Bambusa Therapeutics is a rapidly growing biotechnology company specializing in developing transformative inflammatory and immunological therapeutics. Based in the vibrant Boston Seaport area, Bambusa's mission is to advance the field of immunology with cutting-edge solutions.
Location: United States
Investors 1
| Date | Name | Website |
| 05.07.2025 | INCE Capit... | incecap.co... |
Mentions in press and media 13
| Date | Title | Description |
| 01.04.2026 | Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting | - Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 infla... |
| 19.03.2026 | Bambusa Therapeutics Appoints Todd James Chief Financial Officer | - Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in senior executive roles at Acceleron Pharma prior to its $11.5 b... |
| 30.01.2026 | Bambusa Therapeutics Presented at the 44th Annual J.P. Morgan Healthcare Conference | Bambusa Therapeutics, a portfolio company of INCE Capital, was invited to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13. Bambusa Therapeutics is a clinical-stage biotechnology company advancing next-generation b... |
| 27.11.2025 | INCE Capital’s Portfolio Company Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs | Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), announced the completion of its oversubscribed Series A-2 f... |
| 17.11.2025 | Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs | BOSTON, Nov. 17, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the c... |
| 17.11.2025 | Bambusa Therapeutics Closes Series A-2 Financing | Bambusa Therapeutics, Inc., a Boston, MA-based clinical-stage biotechnology company advancing bispecific antibodies for immunology and inflammation (I&I), closed its Series A-2 financing of undisclosed amount. Backers included Athos KG,... |
| 25.09.2025 | Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001 | BOSTON, Sept. 25, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation, today announced two landmark ... |
| 04.06.2025 | A New Dawn in Cancer Treatment: EBC-129 and BBT002 Lead the Charge | In the ever-evolving landscape of cancer treatment, two innovative therapies are making headlines: EBC-129 and BBT002. Both represent a significant leap forward in the fight against cancer and inflammatory diseases. Their development showca... |
| 30.05.2025 | Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Ap... | Preclinical data with BBT002 demonstrate its best-in-disease potential for improved efficacy and dosing convenience across respiratory, dermatology, and gastroenterology indications Interim safety and pharmacokinetic data from BBT002-01 stu... |
| 28.02.2025 | Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other... | Preclinical data with BBT001 demonstrate its best-in-disease potential for improved efficacy and dosing convenience compared to approved biologics in atopic dermatitis Interim safety and pharmacokinetic data from healthy volunteers anticipa... |
Show more